The Clinical Trials Office of the UNMC Eppley Cancer Center participates in the activation and conduct of clinical cancer research at the Cancer Center. This includes assistance with protocol development, coordination of initial and periodic reviews submitted to the Institutional Review Board, data coordination and collection, and coordinates supervision of appropriate clinical trials by the Audit Committee and the Data and Safety Monitoring Committee. Since the last review (7/1/99 through 6/30/03), a total of 3171 patients have been entered onto Cancer Center clinical research protocols, of which 1054 patients have been entered onto therapeutic trials and 2117 patients were entered onto correlative clinical research studies, companion studies, and chemoprevention clinical research protocols. During the past four years (7/1/99 - 6/30/03) 385 patients were entered onto investigator-initiated clinical trials. During the past year (7/1/02 - 6/30/03), 41 Cancer NCI-A 40 2 P30 CA036727-20 COWAN, K Center members have utilized this facility, of which 26 had external funding, and 156 clinical research protocols were open to accrual during this period. In the last year (7/1/02-6/30/03), 558 patients were entered onto Cancer Center clinical research protocols, of which 310 patients (or 56% of the total patients) were entered onto therapeutic trials. Over the last year, the Cancer Center has undertaken several initiatives to enhance clinical research activities by increasing the support of the administration of the Clinical Trials Office, consolidation of the administrative staff of Clinical Trials Office in a central location in the Lied Transplant Center and the establishment of a Data and Safety Monitoring Committee.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA036727-20
Application #
6998302
Study Section
Subcommittee G - Education (NCI)
Project Start
2004-09-20
Project End
2009-07-31
Budget Start
2004-09-20
Budget End
2005-07-31
Support Year
20
Fiscal Year
2004
Total Cost
$25,104
Indirect Cost
Name
University of Nebraska Medical Center
Department
Type
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Barkeer, Srikanth; Chugh, Seema; Karmakar, Saswati et al. (2018) Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells. BMC Cancer 18:1157
Cserhati, Matyas F; Mooter, Mary-Ellen; Peterson, Lauren et al. (2018) Motifome comparison between modern human, Neanderthal and Denisovan. BMC Genomics 19:472
Napon, Geoffroy; Dafferner, Alicia J; Saxena, Ashima et al. (2018) Identification of Carboxylesterase, Butyrylcholinesterase, Acetylcholinesterase, Paraoxonase, and Albumin Pseudoesterase in Guinea Pig Plasma through Nondenaturing Gel Electrophoresis. Comp Med 68:367-374
Luan, Haitao; Mohapatra, Bhopal; Bielecki, Timothy A et al. (2018) Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program. Cancer Res 78:2524-2535
Rana, Sandeep; Sonawane, Yogesh A; Taylor, Margaret A et al. (2018) Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy. Bioorg Med Chem Lett 28:3736-3740
Azadmanesh, Jahaun; Borgstahl, Gloria E O (2018) A Review of the Catalytic Mechanism of Human Manganese Superoxide Dismutase. Antioxidants (Basel) 7:
Haney, Staci L; Chhonker, Yashpal S; Varney, Michelle L et al. (2018) Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor. Invest New Drugs 36:810-818
Chhonker, Yashpal S; Haney, Staci L; Matthiesen, Robert A et al. (2018) Quantitative determination of a potent geranylgeranyl diphosphate synthase inhibitor using LC-MS/MS: Derivatization and application. J Pharm Biomed Anal 153:22-28
Lockridge, Oksana; David, Emilie; Schopfer, Lawrence M et al. (2018) Purification of recombinant human butyrylcholinesterase on Hupresin®. J Chromatogr B Analyt Technol Biomed Life Sci 1102-1103:109-115
Saxena, Sugandha; Hayashi, Yuri; Wu, Lingyun et al. (2018) Pathological and functional significance of Semaphorin-5A in pancreatic cancer progression and metastasis. Oncotarget 9:5931-5943

Showing the most recent 10 out of 1372 publications